Medtronic's Reimbursement Win Resets the Clock on Two Cardiovascular Bets

AMA grants Category I CPT codes to Medtronic's Altaviva and Symplicity Spyral, effective January 2028, as FDA clears Affera Prism-2 software.

Medtronic has cleared one of the more stubborn hurdles standing between its cardiovascular pipeline and broad commercial adoption in the United States. The American Medical Association has granted Category I CPT codes to the company's Altaviva implantable neuromodulation system and its Symplicity Spyral renal denervation platform — a reclassification that replaces the temporary Category III designations those therapies had been operating under.

The new billing codes take effect in January 2028. In the American reimbursement architecture, that shift matters enormously: Category I status is widely treated as the gateway to routine, automated coverage decisions by payers, whereas Category III codes frequently leave clinicians navigating case-by-case reviews. For hospitals weighing whether to invest in the catheter systems behind Altaviva and Symplicity Spyral, the AMA's decision removes a meaningful layer of financial guesswork.

A Cardiology Cluster Takes Shape

The reimbursement news arrived alongside a burst of regulatory activity in Medtronic's heart business. On Wednesday, the FDA cleared the Affera Prism-2 mapping software, which simultaneously secured the European CE mark. The company also picked up CE certification for its PulseSelect ProxBox adapter and the accompanying Proximity Indicator software.

Taken together, these clearances point toward something more cohesive than a string of isolated approvals. Medtronic is assembling an integrated electrophysiology ecosystem — mapping, ablation and accessory hardware that can be sold as a package to cath labs already familiar with the franchise. That kind of bundling tends to matter when hospitals decide which vendor's platform to standardize on.

The pipeline in peripheral vascular intervention is moving as well. The FDA granted Breakthrough Device designation on Wednesday to IN.PACT BTK, Medtronic's drug-coated balloon catheter. The company intends to run a global randomized pivotal trial enrolling roughly 400 patients.

The Gap Between Approval and Revenue

What the AMA decision does not do is generate near-term income. The codes only become payable in January 2028, leaving clinicians to work with the provisional Category III framework for well over a year. That lag can temper how quickly case volumes ramp, even when the clinical rationale for a procedure is formally recognized.

For investors, this creates an unusual setup: the medical value of Symplicity Spyral and Altaviva now carries official validation, but the financial payoff lands in future reporting periods. Whether the market is willing to price that in ahead of time — or waits for evidence in the income statement — is the open question.

Recent Stumbles Still Weigh

The operational backdrop has not been kind. Roughly three weeks ago, Medtronic's announced spin-off of its diabetes unit MiniMed knocked 4.9% off the share price. A regulatory product recall about two weeks ago cost another 4.8%. The company did raise its annual guidance around the same period, yet the stock has still given up 2.7% since then.

Those setbacks explain why the current valuation carries a discount that the reimbursement decision alone may not erase. If further recalls surface or clinical programs slip, the gap between regulatory progress and commercial reality could persist.

The IN.PACT BTK trial carries its own execution risk. Enrolling 400 patients across global sites introduces recruitment and timeline uncertainties, and a missed primary endpoint would undercut one of the more promising growth stories in the vascular segment.

What to Watch Next

Medtronic shares changed hands at EUR 77.32 on Friday, up 0.5%, giving the company a market capitalization of EUR 98.89 billion. The stock's ability to hold its recent interim low — and the smooth integration of the newly cleared Affera and PulseSelect software across US and European markets — will shape sentiment in the near term.

The next hard milestone is the launch of patient enrollment for the IN.PACT BTK study. Quarterly reports will show whether demand for the Affera and PulseSelect components is building as hoped. Until day-to-day execution catches up with the regulatory wins, the January 2028 reimbursement start date remains a promise rather than a catalyst.